TGT. A. Gomova

T. A. Gomova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


T. A. Gomova has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multimorbidity, risk factors and causes of death in patients with cardiovascular diseases during long-term posthospital monitoring

    by M.M. Loukianov, T.A. Gomova, Shepel, E.Yu. Andreenko, E.Yu. Okshina, N.N. Kuzina, A.G. Soplenkova, E.V. Stepanova, M.N. Valiakhmetov, A.A. Savishceva, et al.

    Objective. To conduct a comparative analysis of the frequency, causes, and risk factors of death in patients with cardiovascular diseases according to long-term follow-up after hospitalization in various departments of a multifaceted hospital. Materials and methods. Multimorbidity, history of coronavirus infection (COVID-19), frequency, causes, and risk factors of death during the follow-up period of 2.6 [2.3; 2.8] years were assessed in 13/551 patients with cardiovascular diseases (CVD) after discharge from the various departments in the proSpective registry Of a multiFaceted medIcal cenTer (SOFIT). Results. Two or more CVDs and non-cardiac diseases were reported in 81.4% of cases, cardiovascular multimorbidity in 47.5%, non-cardiac multimorbidity in 52.4%, and their combination in 17.9% of patients. 15.5% of patients died. On average, the highest mortality per year was reported in patients discharged from the emergency cardiology department (9.0%), the lowest from the cardiology department (4.4%), and from the departments of therapeutic and other profiles — 5.6 and 6.6%, respectively. The proportion of deaths from cardiovascular causes among deceased patients with CVD was 35.8%. The mortality risk was associated with age and male sex, increased by 1.2—1.7 times in the presence of a history of myocardial infarction, cerebrovascular accident, diabetes mellitus, chronic obstructive pulmonary disease, or inpatient treatment for COVID-19. The COVID-19-related mortality risk increased with age, and was several times lower in patients with a history of previous outpatient and inpatient treatment for this disease (8.2 and 4.9 times). Conclusion. In patients with cardiovascular diseases, monitored in the long-term follow-up after treatment in a multifaceted hospital, multimorbidity was reported in 81.4% of cases, both cardiovascular and non-cardiac multimorbidity in about 50% of cases, and their combination in 17.9% of patients. 15.5% of patients died. The mean proportion of deaths per year was the highest among those discharged from the emergency cardiology department (9.0%), and the lowest from the cardiology department (4.4%). Cardiovascular causes of death were reported in a minority of deceased cardiovascular patients due to non-cardiac comorbidity. The risk of death from all and cardiovascular causes was associated with age, male sex, previous myocardial infarction, cerebrovascular accident, diabetes mellitus, chronic obstructive pulmonary disease, and a history of inpatient treatment for COVID-19. In patients with cardiovascular diseases, the higher risk of COVID-19-related mortality associated with age was several times lower in those with a history of the disease.

  • Open Access

    Efficacy and safety for preventing of venous thromboembolic complications in high-risk pregnant women: results of the «BEREG» pregnant women registry

    by R. I. Stryuk, O. V. Krikunova, E. E. Lokshina, T. A. Gomova, E. E. Fedotova

    Introduction. Recently, along with increasing women age who become pregnant and number of patients with extragenital pathology, a greater role has been referred to preconception preparation and implementation of preventive measures aimed at minimizing development of severe and often fatal conditions, particularly venous thromboembolic events (VTE), which are one of the lead cause of maternal and perinatal mortality in developed countries. Aim: to analyze the effectiveness and safety of thromboprophylaxis in pregnant women with high VTE risk in real-world clinical practice. Materials and Methods . The analysis was based on data obtained in the observational (cohort) study "Assessment of the clinical condition of pregnant women during gestation and childbirth in the early postpartum period and 12 months after childbirth, as well as analysis of perinatal outcomes, the condition of the fetus, newborn, and the quality of treatment for these patients" – the "BEREG" register. Inclusion criteria: pregnancy diagnosis at the first visit, the patient's written informed consent and their permanent residence in Tula or the Tula Region. Non-inclusion criteria: the patient's refusal to sign informed consent and their residence in other regions. All patient data were retrieved from outpatient and inpatient records and included complaints, medical history, information about previous and current illnesses, VTE risk factors, anthropometric data such as height, body weight, and body mass index at the time of pregnancy, as well as the type and dose of antithrombotic medication. Special attention was paid to the obstetric history, including the course of previous and current pregnancies, perinatal outcomes and delivery methods. VTE and thromboprophylaxis tactics were assessed using the "Antenatal and Postnatal Assessment of Risk Factors and Pregnancy Management" scale. The newborn's condition was evaluated by assessing birth height, weight and the Apgar score at 1 and 5 minutes of life. Results. A total of 3214 pregnant women aged from 15 to 46 years were included in the registry, of which 330 (10.3 %) women who received antithrombotic therapy with anticoagulants and/or antiplatelet agents, including 217 (65.8 %) pregnant women receiving combination therapy calcium nadroparin (Fraxiparin) 0.3 ml (2850 IU anti-Xa) subcutaneously per day combined with acetylsalicylic acid (ASA) 150 mg/day per os (group 1) and 113 woman (34.2 %) – monotherapy with ASA 150 mg/day once per os (group 2). The groups were comparable in major clinical and laboratory characteristics. Patient management analysis showed that no cases of VTE, maternal mortality, allergic side effects, thrombocytopenia or heparin-induced thrombosis were observed in either group. However, only in the group of patients receiving ASA monotherapy there were recorded complications such as bleeding during childbirth (n = 1) and fetal death (n = 3), however, not allowing to establish a clear link with the medicine intake due to the small number of observations. It is noteworthy that doctors were not sufficiently informed about the need to use VTE risk assessment scales to optimize the management strategy, as evidenced by the lack of instructions on their use in medical records. Conclusion. The registry showed the effectiveness and safety of thromboprophylaxis based on the 0,3 ml Fraxiparin in high-risk pregnant women in real-world clinical practice, which is confirmed by the lack of VTE, bleeding, maternal death, allergic side effects, thrombocytopenia and heparin-induced thrombosis. Of note, due to insufficient doctors' alertness about a need to apply VTE risk assessment scale for objectifying treatment strategy, the prophylactic options were chosen arbitrarily: combined therapy with low molecular weight heparin and ASA, or ASA monotherapy.


  • Open Access

    Patients with atrial fibrillation after discharge from a multidisciplinary hospital: analysis of death risk and its causes based on 10-year follow-up data

    by M. M. Luk'YAnov, T. A. Gomova, S. Yu. Martsevich, R. N. Shepel, A. G. Soplenkova, A. A. Smirnov, M. N. Valiakhmetov, E. V. Stepanova, A. A. Savishcheva, O. M. Drapkina, et al.

    Aim. To evaluate the outcomes of 10-year follow-up of patients with atrial fibrillation (AF) after hospitalization in various departments of a multidisciplinary hospital and to determine the most significant prognostic factors associated with a high death risk. Material and methods . In the outpatient registry RECVAZA-AF Tula after discharge from a multidisciplinary hospital, the outcomes for the period 2013-2024 (follow-up, 7,9±3,7 years) were assessed in 1159 patients with AF (age, 69,2±9,8 years; men, 48,0%). Information on fatal outcomes was obtained from the Regional Information System of the Tula Oblast. Results . Over 10 years, 509 (43,9%) patients with AF died. The highest proportion of deaths was among those who had stroke and myocardial infarction (MI) — 55,1 and 52,9%, respectively, with permanent AF (51,4%), at the age of ≥80 years (66,4%). High all-cause and cardiovascular death risk was associated with the following factors: age (hazard ratio (HR)=1,04 and HR=1,06; pConclusion . Over 10 years after discharge from a multidisciplinary hospital, 43,9% of patients with AF died. The mortality rate was highest in AF with prior stroke and MI, with permanent AF, and at an age of ≥80 years. Prognostically unfavorable factors also included diabetes, chronic obstructive pulmonary disease, low hemoglobin levels, and systolic blood pressure <110 mm Hg. The lowest mortality rate was among patients discharged from cardiology (excluding emergency cardiology) and internal medicine departments, and the highest one was among those discharged from emergency cardiology, neurology, and surgery departments.


  • Open Access

    Organizational and applied aspects of follow-up monitoring of patients with prediabetes by a primary care physician. Expert council resolution

    by O. M. Drapkina, E. A. Lavrenova, D. I. Abdulganieva, T. A. Gomova, M. A. Livzan, N. P. Sanina, Yu. A. Sharapova, R. N. Shepel, A. A. Yafarova

    The steady increase in the prevalence of carbohydrate metabolism disorders worldwide, with the vast majority of type 2 diabetes (T2D), specifies the need to improve disease prevention measures. A special niche in the preventive continuum is occupied by early carbohydrate metabolism disorders, the treatment of which makes a significant contribution to T2D prevention. The absence of a characteristic clinical performance, inadequate apprehensive attitude of healthcare professionals contributes to unnoticed development of carbohydrate metabolism disorders, while progressive disorders lead to micro-, macrovascular complications and the manifestation of T2D. On September 16, 2024, under the chairmanship of Academician of the Russian Academy of Sciences O. M. Drapkina and under the aegis of the Russian Society for the Prevention of Noncommunicable Diseases, the Expert Council was held on Organizational and Applied Aspects of Follow-up Monitoring of Patients with Prediabetes by a General Practitioner. The meeting was attended by the main external experts in internal medicine of regional health protection executive authorities, leading experts of the National Medical Research Center for Therapy and Preventive Medicine and regional branches of the Russian Society for the Prevention of Noncommunicable Diseases, who presented current related problems and proposals for their solution. The Expert Council resolution is presented in this article.


  • RegiStry Of the multiFaceted medIcal cenTer (SOFIT): the main tasks, development, and the first results

    by M.M. Loukianov, T.A. Gomova, A.A. Savishceva, E.YU. Andreenko, S.M. Androsov, Shepel, O.M. Drapkina

    ЦЕЛЬ ИССЛЕДОВАНИЯ Описать методологию создания региСтра мнОгопроФИльного медицинского ценТра (СОФИТ) и представить первые результаты в виде оценки демографических характеристик, доли лиц с сердечно-сосудистыми и хроническими некардиальными заболеваниями терапевтического профиля, частоты перенесенной новой коронавирусной инфекции у госпитализированных больных. МАТЕРИАЛ И МЕТОДЫ В СОФИТ включены 21 783 пациента (средний возраст 57,8±16,2 года; 46,5% мужчин), госпитализированных в ГУЗ ТО «Тульская областная клиническая больница» с 01.01.21 по 31.12.21. Оценена информация электронных историй болезни с использованием ресурса медицинской информационной системы. Полученные данные сопоставлены в отделениях кардиологического, терапевтического и других профилей. РЕЗУЛЬТАТЫ У включенных в регистр пациентов доля случаев сердечно-сосудистых заболеваний (ССЗ) составила 65,7%, из них с двумя и более ССЗ было 38,2% пациентов, с 3—4 ССЗ — 11,7%. Доля лиц с ССЗ и/или хронической некардиальной патологией была 84,4%, перенесших COVID-19 — 12,9%. В отделениях кардиологического, терапевтического и других профилей наиболее часто из числа ССЗ регистрировались артериальная гипертония (74,8; 61,5 и 56,9%) и ишемическая болезнь сердца (84,0; 14,7 и 16,8%), а из числа хронических некардиальных заболеваний — болезни органов пищеварения (32,3; 50,1 и 30,2%), ожирение (38,4; 22,7 и 18,0%) и сахарный диабет (23,6; 16,1 и 17,5%). Больные с ССЗ чаще, чем пациенты без ССЗ, переносили COVID-19 (14,8 и 9,3%; p<0,0001). ЗАКЛЮЧЕНИЕ Среди госпитализированных больных как во всем стационаре, так и в анализируемых блоках отделений, большинство имели сердечно-сосудистые и хронические некардиальные заболевания: доля пациентов, перенесших COVID-19, составила 12,9%. У пациентов с сердечно-сосудистыми заболеваниями чаще, чем при отсутствии данной патологии, имелись хронические некардиальные заболевания и COVID-19 в анамнезе. Пациенты с сочетанием ССЗ и хронической некардиальной патологии, включая перенесших COVID-19, являются целевой группой для междисциплинарного взаимодействия при оказании медицинской помощи в многопрофильном стационаре, особенно в отделениях, не относящихся к кардиологическому и терапевтическому профилям.


  • Open Access

    Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes

    by M. M. Loukianov, S. Yu. Martsevich, Yu. V. Mareev, S. S. Yakushin, E. Yu. Andreenko, A. N. Vorobiev, K. G. Pereverzeva, A. V. Zagrebelny, E. Yu. Okshina, Vl. Vl. Yakusevich, et al.

    Aim. To assess in clinical practice the structure of multimorbidity, cardiovascular pharmacotherapy and outcomes in patients with a combination of atrial fibrillation (AF) and chronic heart failure (CHF) based on prospective registries of patients with cardiovascular diseases (CVD).Materials and Methods. The data of 3795 patients with atrial fibrillation (AF) were analyzed within the registries RECVASA (Ryazan), RECVASA FP (Moscow, Kursk, Tula, Yaroslavl), REGION-PO and REGION-LD (Ryazan), REGION-Moscow, REGATA (Ryazan). The comparison groups consisted of 3016 (79.5%) patients with AF in combination with CHF and 779 (29.5%) patients with AF without CHF. The duration of prospective observation is from 2 to 6 years.Results. Patients with a combination of AF and CHF (n=3016, age was 72.0±10.3 years; 41.8% of men) compared with patients with AF without CHF (n=779, age was 70.3±12.0 years; 43.5% of men) had a higher risk of thromboembolic complications (CHA2DS2-VASc – 4.68±1.59 and 3.10±1.50; pConclusion. Patients with a combination of AF and CHF, compared with the group of patients with AF without CHF, were older, had a higher risk of thromboembolic and hemorrhagic complications, they were more often diagnosed with other concomitant cardiovascular and chronic noncardiac diseases, decreased left ventricular ejection fraction, tachysystole, failure to achieve the target blood pressure level in the presence of arterial hypertension. The frequency of prescribing proper cardiovascular pharmacotherapy was higher, albeit insufficient, in the presence of CHF, while the frequency of prescribing anticoagulants was less. The incidence of mortality from all causes, the development of non-fatal myocardial infarction and cerebral stroke, as well as the incidence of hospitalizations for CVDs were higher in AF associated with CHF.


  • Open Access

    Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the REСVASA Registries)

    by M. M. Loukianov, S. Yu. Martsevich, E. Yu. Andrenko, S. S. Yakushin, A. N. Vorobiev, K. G. Pereverzeva, A. V. Zagrebelny, Е. Yu. Okshina, Vl. Vl. Yakusevich, E. M. Pozdnyakova, et al.

    Aim. Assess the structure of comorbid conditions, cardiovascular pharmacotherapy and outcomes in patients with atrial fibrillation (AF) and concomitant coronary artery disease (CAD) included in the outpatient and hospital RECVASA registries.Materials and methods. 3169 patients with AF were enrolled in outpatient RECVASA (Ryazan), RECVASA AF-Yaroslavl registries and hospital RECVASA AF (Moscow, Kursk, Tula). 2497 (78.8%) registries of patients with AF had CAD and 703 (28.2%) of them had a previous myocardial infarction (MI).Results. There were 2,497 patients with a combination of AF and CAD (age was 72.2±9.9 years; 43.1% of men; CHA2DS2-VASc – 4.57±1.61 points; HAS-BLED – 1.60±0,75 points), and the group with AF without CAD included 672 patients (age was 66.0±12.3 years; 43.2% of men; CHA2DS2-VASc – 3.26±1.67 points; HAS-BLED – 1,11±0.74 points). Patients with CAD were on average 6.2 years older and had a higher risk of thromboembolic and hemorrhagic complications (pConclusion. 78.8% of patients from AF registries in 5 regions of Russia were diagnosed with CAD, of which 28.2% had previously suffered myocardial infarction. Patients with a combination of AF and CAD more often than in the absence of CAD had hypertension, chronic heart failure, diabetes, chronic kidney disease and anemia. Patients with the previous MI had higher incidence of diabetes than those without the previous MI. The frequency of proper cardiovascular pharmacotherapy was insufficient, and to a greater extent in the presence of CAD and the previous MI than in their absence. All-cause mortality was recorded in patients with a combination of AF and CAD more often than in the absence of CAD. All-cause mortality and the incidence of nonfatal myocardial infarction were higher in patients with AF and the previous MI than in those without the previous MI. The presence of CAD and, in particular, the previous MI, was significantly associated with a higher risk of death, as well as a higher risk of developing a combined cardiovascular endpoint.


  • Open Access

    Adherence to Statins Therapy of High and Very High Cardiovascular Risk Patients in Real Clinical Practice: Diagnostics and Possible Ways to Solve the Problem (According to the PRIORITY Observational Study)

    by S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, N. A. Dmitrieva, S. V. Blagodatskikh, O. V. Lerman, T. A. Gomova, S. I. Drozdetsky, V. V. Skibitskiy, E. A. Kudryashov, et al.

    Aim. To study adherence to treatment with generic statins prescribed to patients with high and very high cardiovascular risk in routine clinical practice, as well as the possible impact of educational training of doctors on compliance with clinical guidelines and changes in patient adherence to treatment. Material and methods. The study was prospective, with educational training for physicians on the main provisions of current clinical guidelines prior to the program. It included 3 visits over 12 weeks: inclusion visit (V0), and visits after 1 and 3 months of follow-up (V1 and V3). The use of generic atorvastatin or rosuvastatin was recommended for all patients. To assess adherence the following surveys were used: medical survey (all visits), the original questionnaire to assess the potential and the actual commitment to taking statins and the causes of non-adherence, and the Morisky-Green 8-question test (visits V0 and V3) to evaluate overall adherence to drug treatment. The patients who started the drug taking according to the medical recommendations and continued it during the study were considered as adherents. Patients who started but stopped taking the drug for 12 weeks were considered as partially non-adherent. Patients who refused to take the recommended statin were considered as non-adherents. The prescribed doses of statins and medical tactics in the titration of doses, as well as the achievement of the target level of low-density lipoprotein cholesterol (LDL cholesterol) were evaluated. Results. 112 (37.5%) of the 298 patients with baseline indications for taking statins did not take these drugs. According to the medical survey at V0 a total of 286 (96%) patients were potential adherents to medical recommendations; at V3 262 (88%) patients were adherent to statin treatment; 34 patients were partially non-adherent, 1 – was non-adherent, and 1 – dropped out of the study immediately after V0. According to the original questionnaire, potential adherence was assessed in 281 patients: 244 (86.8%) were potentially adherent, 37 (13.2%) – partially non-adherent. At V3, out of 294 patients who filled in the original questionnaire, 260 (88.5%) were adherent, 26 (8.8%) – partly non-adherent, 8 (2.7%) – nonadherent. The Morisky-Green questionnaire was filled in by 292 patients: at V0, 106 patients (36.3%) had treatment adherence, non-adherence – 186 patients (63.7%). By V3, an increase in total adherence was found: 159 patients (54.5%) were adherent, and 133 (45.5%) – non-adherent. The lipid profile was evaluated in 231 patients in V1 and in 285 ones – in V3. The target LDL cholesterol level was reached by V1 in 47 (20.3%) patients, and in 184 (79.7%) patients – was not. Dose titration occurred in 56 patients. By V3, 121 (42.4%) patients reached the target level of LDL cholesterol, and 164 – did not. The results of the lipid profile analysis were erroneously interpreted in 21 patients. Conclusion The results of the medical survey and the original questionnaire for assessing adherence predominantly coincided. The Morisky-Green test does not accurately reflect patients' commitment to taking a particular drug. Clinical inertness of doctors in the titration of statin doses and achievement of target LDL cholesterol levels were found as well as erroneous interpretation of the LDL cholesterol level. Educational trainings for doctors had a positive effect on the implementation of clinical guidelines, and also contributed to increasing patient adherence to medical recommendations.


  • Open Access

    Features and main problems of treating patients with high and very high cardiovascular risk with statins in real clinical practice (according to the data of the “PRIORITET” research)

    by S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, N. A. Dmitrieva, T. A. Gomova, S. I. Drozdetsky, E. A. Kudryashov, O. V. Lerman, N. F. Puchinyan, V. V. Skibitsky, et al.

    Aim. To determine the features and main problems of statin therapy, as well as assess the possibility of achieving the target level of lipid pattern in patients with high and very high cardiovascular risk (CVR) in real clinical practice.Material and methods. The design of the “PRIORITET” observational program is an open observational study. Patients with high and very high CVR were divided into 3 groups in accordance with the initial data: (1) not taking statins, (2) taking statins, but not reaching the target low-density lipoprotein cholesterol (LDL-C) level, (3) taking statins with the achievement of the target LDL-C level, which is justified in replacing the statin inside the class — adverse effects (AE), high price, etc. Within 12 weeks 3 visits of patients to hospitals were carried out: baseline visit (B0), visit 1 month after the study initiation (B1) and visit 3 months after the study initiation (B3). The choice of atorvastatin or rosuvastatin was assessed by the doctors.Results. Groups 1, 2 and 3 included 112, 170 and 16 people, respectively. At B0, 145 (48,7%) patients were prescribed atorvastatin, and 153 (51,3%) — rosuvastatin. Three people dropped out of the study to B3, 295 patients completed the program. Lipid pattern of 285 patients were analyzed: 121 (41%) people (101 with very high CVR and 20 with high CVR) achieved the target LDL-C level, the remaining 164 (59%) patients (CVR — 156 and 8, respectively) — no. The most pronounced dynamics of LDL=C level was revealed in group 1, the differences between group 1 and groups 2 and 3 are highly statistically significant (pConclusion. The main problems of statin therapy in real clinical practice are the wrong interpretation of reaching the target level of LDL-C, inertness of doctors in titrating of statins doses and achieving the target level of lipid pattern. It may be the cause of reduced efficiency and deterioration of lipid-lowering therapy results in patients with high and very high CVR. The results of the “PRIORITET” study demonstrated the possibility of improving the practice of statins use and its accordance with clinical guidelines.Skibitsky V. V. on behalf of the working group of the “PRIORITET” researchWorking Group of the “PRIORITET” study: Voronina V. P. (Moscow), Zelenova T. I. (Moscow), Sladkova T.A. (Moscow), Alekseeva A. I. (Tula), Barabanova T. Yu. (Tula), Zotova A. S. (Tula), Kolomeitseva T. M. (Tula), Prikhod’ko T. N. (Tula), Pazelt E. A. (Nizhny Novgorod), Khramushev N. Yu. (Nizhny Novgorod), Skibitsky A. V. (Krasnodar), Alekseeva V. V. (Saratov), Lazareva E. V. (Saratov).


  • Open Access

    STUDY OF PATIENTS ADHERENCE TO TREATMENT IN METABOLIC SYNDROME, WITH THE NOVEL COMBINATION ANTIHYPERTENSION COMPOUND OF RAMIPRIL AND AMLODIPINE BY THE DATA OF OBSERVATIONAL STUDY GRANAT-1

    by S. Yu. Martsevich, Yu V. Lukina, E. P. Kutishenko, V. P. Voronina, N. A. Dmitrieva, A. V. Zakharova, O. V. Lerman, Array А. Гарганеева, T. A. Gomova, S. I. Drozdetsky, et al.

    Цель. Изучить некоторые аспекты приверженности антигипертензивной терапии (АГТ) пациентов с артериальной гипертонией (АГ) и метаболическим синдромом (МС) на примере фиксированной комбинации рамиприла и амлодипина в рамках программы ГРАНАТ-1 (Наблюдательная проГРАмма за пациеНтами с Артериальной гиперТонией и метаболическим синдромом). Материал и методы. В исследование включен 101 пациент, имевший ранее подтвержденные диагнозы АГ и МС, все больные полностью завершили участие в программе. Всем пациентам, согласившимся принять участие в программе, был рекомендован прием антигипертензивного препарата (АГП) — фиксированной комбинации рамиприла и амлодипина (Эгипрес) в различных дозировках, выбор которых определял лечащий врач в рамках рутинной клинической практики. Каждого пациента приглашали на 4 визита в течение 5 мес. с интервалом 1-2-2 мес. (В1-В2-В3-В4). Для оценки общей приверженности врачебным рекомендациям (ВР) во время первого и заключительного визитов больные заполняли тест Мориски-Грина (М-Г), состоящий из 4 вопросов, во время всех визитов у пациентов оценивали величину артериального давления (АД), частоту сердечных сокращений; во время В2-В4 проводили мониторинг нежелательных явлений (НЯ). Также оценивались фактическая приверженность больных ВР по приему Эгипреса, и активность врачей в достижении целевых уровней АД у пациентов, участвовавших в программе. Результаты. Рекомендованный АГП начали принимать 95 больных, к концу программы Эгипрес принимали 92 пациента, 9 человек принимали другую АГТ. 90 человек достигли целевого уровня АД; 81 — при приеме Эгипреса. Эффект назначенной на В1 АГТ у большинства больных проявился уже через 1 мес. наблюдения (визит В2): у каждого третьего пациента был достигнут целевой уровень АД, в среднем уровень систолического АД снизился на 17,2 мм рт.ст., диастолического АД — на 7,7 мм рт.ст. (визит В2), и на 31,0 мм рт.ст. и 16,1 мм рт.ст., соответственно, — визит В4. Всего было зарегистрировано 3 НЯ лекарственной терапии, вероятней всего обусловленные действием амлодипина. Отмечено существенное улучшение общей приверженности пациентов лечению: если в начале программы по результатам теста М-Г были привержены только 22 (21,8%) больных, то на заключительном визите — 70 (69%) пациентов. В трех случаях отмечена инертность врачей в достижении целевого уровня АД. Заключение. Однократное применение фиксированной комбинации амлодипина и рамиприла, ее высокие эффективность и безопасность в сочетании с регулярным посещением врача способствуют повышению общей приверженности больных назначенному лечению.